Key statistics
As of last trade Innate Pharma SA (IDD:STU) traded at 1.92, 1.80% above its 52-week low of 1.88, set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.91 |
---|---|
High | 1.92 |
Low | 1.91 |
Bid | 1.94 |
Offer | 1.98 |
Previous close | 1.91 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.97m |
Free float | 60.70m |
P/E (TTM) | -- |
Market cap | 158.05m EUR |
EPS (TTM) | -0.4215 EUR |
Data delayed at least 15 minutes, as of Oct 08 2024.
More ▼
Press releases
- Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
- Innate Pharma Reports First Half 2024 Business Update and Financial Results
- Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
- Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
- Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
More ▼